Deutsche Bank’s Calidi Biotherapeutics CLDI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-1,162
Closed -$1.46M 3726
2023
Q2
$1.46M Hold
1,162
﹤0.01% 1775
2023
Q1
$1.43M Buy
+1,162
New +$1.42M ﹤0.01% 1879
2022
Q3
Sell
-833
Closed -$994K 3985
2022
Q2
$994K Hold
833
﹤0.01% 2189
2022
Q1
$989K Hold
833
﹤0.01% 2352
2021
Q4
$981K Buy
+833
New +$982K ﹤0.01% 2450

Other funds holding CLDI

Deutsche Bank's CLDI Position: Q3 2023 in Review

Deutsche Bank sold out of Calidi Biotherapeutics (CLDI) in Q3 2023, closing a stake of 1,162 shares — an estimated $1.46M sold.

Deutsche Bank first reported a position in CLDI in Q4 2021 and held it in 5 quarters. The position peaked at $1.46M in Q2 2023. 12 funds tracked by Wall St. Rank hold CLDI as of Q3 2023.

  • Deutsche Bank reported no remaining Calidi Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Deutsche Bank sold 1,162 Calidi Biotherapeutics shares in Q3 2023, an estimated $1.46M.
  • Deutsche Bank first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 5 quarters.
  • Deutsche Bank's Calidi Biotherapeutics position peaked at $1.46M in Q2 2023.
  • 12 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2023.

Based on Deutsche Bank's 13F filing for Q3 2023, filed 9 Nov 2023.